A phase III clinical trial is testing this agent in the adjuvant setting following surgery in advanced bladder cancer with susceptible FGFR3 genetic alterations (ClinicalTrials.gov Identifier, NCT04197986). This evidence concerns the gene FGFR3 and urinary bladder cancer.